INEX Innovate

17/01/2024

𝐓𝐡𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐓𝐢𝐦𝐞𝐬 feature on INEX Innovate - chronicling our incredible journey and remarkable growth in the realms of “chromosomes, cancer, and COVID”, as part of the Enterprise 50 Awards 📈🧬

This series is part of the Enterprise 50 Educational project with the NUS Business School, National University of Singapore.

The annual E50 Rankings is co-organised by The Business Times and KPMG, sponsored by OCBC Bank and supported by Enterprise Singapore, SGX Group and Singapore Business Federation.

10/01/2024

Luxury lifestyle, news and business publication - LUXUO chronicles INEX Innovate's ascent in the world of women’s and fetal maternal health in a wide ranging interview with INEX Chief Executive Kane Black where they discuss INEX’s role on the future of fetal-maternal care and oncology alongside INEX’s ambition to “democratise diagnostics” and Kane’s journey through the medtech industry.

https://www.luxuo.com/business/inex-chief-executive-kane-black-on-innovating-the-future-of-medtech.html

LUXUO speaks to the man making waves in medical research and innovations in the MedTech sector alongside the growth of INEX.

30/11/2023

Today until 3 December INEX Innovate 🇸🇬 is on the tech island of Taiwan 🇹🇼 exhibiting at the 7th Annual Healthcare+® Expo, the largest medical trade fair in the APAC region.

At this year’s expo, officiated by Taiwanese President Tsai Ing-wen, INEX Innovate is exhibiting together with our colleagues from Yourgene Health Taiwan where we are showcasing our technologies in the fetal maternal and women’s health space. Including our NIPT solutions, Preeclampsia Screening, and CarrierGene, In addition to our oncology test platforms including, OvaCis® our test for ovarian cancer, epiHERA® for the detection of endometrial cancer and epiDX® for the detection of breast cancer.

Taiwan 🇹🇼 has emerged as a global leader in advanced medical technology industries, showcasing a remarkable blend of innovation, research prowess, and manufacturing excellence. Renowned for its cutting-edge medical device sector, Taiwan has consistently produced high-quality and sophisticated equipment, ranging from diagnostic tools to precision medical instruments.

If you are visiting the event please come by and say hello!

09/11/2023

INEX Innovate is proud that Chief Technology Officer Dr. Chia-Pin Chang was selected to share the INEX journey of technological advancement in women’s health diagnostics in a presentation titled From the Bench to the Bedside at Enterprise Singapore's 🇸🇬 SWITCH Singapore's Agency for Science, Technology and Research (A*STAR) SME Tech Day 2023 event.

At the event officiated by Ministry Of Trade and Industry Minister Gan Kim Yong, Dr. Chang shared the company's journey in the development of one of its products - , an intraoperative ovarian cancer rapid test.

Ovarian Cancer is one of most deadly gynaecological cancer in the world. More than 200,000 people die in the Ovarian Cancer worldwide annually. And it starts from an ovarian cyst. 1 in 10 women would have ovarian cyst during their life time.

To know more about OvaCis®, please visit https://lnkd.in/gGTxrAV5

31/08/2023

𝐈𝐍𝐄𝐗 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐓𝐡𝐞 𝐋𝐚𝐮𝐧𝐜𝐡 𝐨𝐟 𝐞𝐩𝐢𝐇𝐄𝐑𝐀®, 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐚𝐧𝐲'𝐬 𝐓𝐞𝐬𝐭 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐄𝐚𝐫𝐥𝐲 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐄𝐧𝐝𝐨𝐦𝐞𝐭𝐫𝐢𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 - 𝐚𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐛𝐲 𝐁𝐢𝐨𝐒𝐩𝐞𝐜𝐭𝐫𝐮𝐦. 🇸🇬

INEX Innovate, is pleased to announce the launch of epiHERA® the company’s early endometrial cancer detection technology, unveiled at the 2023 Singapore International Congress of Obstetrics and Gynaecology (SICOG).

With 1 in 10 women suffering from abnormal bleeding during their lifetime and requiring an invasive specialist biopsy procedure to rule out endometrial cancer. By using the widely accepted PAP smear or HPV sampling procedure instead, epiHERA® holds great potential as an adjunct tool to help clinicians right at the clinic.

At the core of epiHERA® lies an advanced PCR test designed to identify epigenetic alterations in genes linked to the presence of endometrial cancer. This streamlined process concludes within approximately six hours.

Made in Singapore 🇸🇬 in collaboration with our partner JH CisPoly, INEX Innovate's epiHERA® technology addresses a crucial gap in current diagnostics by promoting equitable access to testing for vulnerable women.

The novel methodology optimizes sample acquisition, significantly decreasing turnaround time from weeks to days. The scalability of molecular PCR testing assures broad accessibility, further amplifying the impact of epiHERA® within the domain of women's health.

In validation studies undertaken, and ongoing, at The Chinese University of Hong Kong (CUHK) epiHERA® has shown promising results. epiHERA® now is available for Research Use Only.

To find out more please read the article below by BioSpectrum Asia

I IGene NIPT Endometrial Cancer

Novel epiHERA® methodology optimizes sample acquisition, significantly reducing turnaround time from weeks to days, enabling equitable access to critical diagnostics

22/08/2023

𝐈𝐍𝐄𝐗 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 𝐭𝐨𝐝𝐚𝐲 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐌𝐫. 𝐓𝐞𝐝 𝐓𝐚𝐧, 𝐩𝐫𝐞𝐯𝐢𝐨𝐮𝐬𝐥𝐲 𝐃𝐞𝐩𝐮𝐭𝐲 𝐂𝐡𝐢𝐞𝐟 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐯𝐞 𝐨𝐟 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞 𝐒𝐢𝐧𝐠𝐚𝐩𝐨𝐫𝐞, 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐚𝐩𝐩𝐨𝐢𝐧𝐭𝐞𝐝 𝐚𝐬 𝐭𝐡𝐞 𝐧𝐞𝐰 𝐂𝐡𝐚𝐢𝐫𝐦𝐚𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐁𝐨𝐚𝐫𝐝 𝐨𝐟 𝐈𝐍𝐄𝐗 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞.

𝐄𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 21 𝐀𝐮𝐠𝐮𝐬𝐭, 𝐓𝐞𝐝 𝐬𝐮𝐜𝐜𝐞𝐞𝐝𝐬 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫 𝐒𝐭𝐞𝐯𝐞 𝐌𝐲𝐢𝐧𝐭, 𝐰𝐡𝐨 𝐫𝐞𝐭𝐢𝐫𝐞𝐝 𝐚𝐟𝐭𝐞𝐫 𝐬𝐞𝐫𝐯𝐢𝐧𝐠 𝐚𝐬 𝐂𝐡𝐚𝐢𝐫𝐦𝐚𝐧 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐩𝐚𝐬𝐭 𝐧𝐢𝐧𝐞 𝐲𝐞𝐚𝐫𝐬.

Mr. Tan has over 30 years of public and private sector experience in policy making, programme development, leadership, coaching and mentoring, governance, and risk management.

Mr. Tan is now an Enterprise Fellow of Enterprise Singapore. Additionally, Mr. Tan is the Operating Partner of Heliconia Capital Management, a wholly owned subsidiary of Temasek.

Mr. Tan is Board Director of Singapore SGX Mainboard-listed Q & M Dental Group (Singapore) Limited, and Board Director of China Life Insurance (Singapore) Pte. Ltd. – a subsidiary of China Life Insurance Group, a Fortune 500 company. He is also the Chairman of IPI that catalyses innovation and Board Director of SEEDS Capital that invests in innovative startups.

Mr. Tan has been appointed an Adjunct Associate Professor of the Nanyang Business School at Nanyang Technological University Singapore.

In 2012, Mr. Tan was awarded the Public Administration Medal (Silver) by the Singapore government.

From the team at INEX we would like to thank Prof Steve Myint for his great contribution to INEX and iGene Laboratory over the past nine years. Prof Myint was instrumental in the merger of Nova Satra Dx. and INEX which saw the creation of INEX Innovate in 2019.

07/03/2023

INEX Innovate is delighted to announce the appointment of Biomed Global as distributor for the launch of OvaCis® - The Company’s Test for Ovarian Cancer in Indonesia, Malaysia, Philippines, Singapore and Thailand.

OvaCis®, is a test kit that identifies benign and malignant ovarian cysts in under 15 minutes. Developed at the National University of Singapore and approved for use in the European Union and the United Kingdom, The OvaCis® Rapid Test OvaCis® is an intra-operative point-of-care medical device that can determine if the ovarian cyst is benign or malignant. 1 in 10 women will at some point of their lifetime develop an ovarian cyst.

| IGene NIPT

13/12/2022

INEX Innovate's Chief Executive Kane Black sits down with The Edge Singapore's journalist Bryan Wu where they discuss our pivot back into core fetal health and women's oncology post COVID, democratising diagnostics and our future IPO plans.

| IGene NIPT

INEX Innovate is addressing unmet clinical needs in women’s and foetal health by democratising diagnostic testing in Asia.

25/11/2022

The team at INEX Innovate is delighted to be named a winner of The Enterprise 50 Awards - ranking 17 of Singapore's 50 most enterprising companies.

Jointly organised by KPMG Singapore and The Business Times, and sponsored by OCBC BankBank. Supporters of the awards include Enterprise Singapore, the Singapore Business Federation and SGX Group the E50 Awards has become the definitive list of the 50 most enterprising, privately-held local companies in Singapore.

Every year, applicants of the E50 Awards are evaluated and ranked using both quantitative and qualitative criteria. Quantitative factors include financial performance indicators such as operating profit before tax, turnover and profit growth. The qualitative criteria include management and marketing strategies such as the applicants’ business models, innovations, management ideals, governance, market branding and overall potential. For more information, please visit

www.enterprise50.org

22/11/2022

INEX Innovate is pleased to announce it has successfully received UK Registration with the Medicines & Healthcare Products Regulatory Agency (MHRA) for it’s OvaCis® Rapid Test for ovarian cancer. 🇬🇧

OvaCis® is a globally patented Point-Of-Care device that discriminates benign from malignant ovarian cysts in an operating theatre setting. The user-friendly rapid test can determine if a cyst, which occurs in 1 in 10 women in their lifetime, is benign or malignant by detecting a protein biomarker called haptoglobin, which is found in ovarian cyst fluid.

The ovarian cancer product recently achieved CE-IVD approval, paving the way for distribution across Europe and now the United Kingdom.



Ovarian Cancer Action | Ovarian Cancer Research Alliance OCRA | Target Ovarian Cancer | Ovacome - The Ovarian Cancer Support Charity | Ovarian Cancer Australia | IGene NIPT

09/11/2022

INEX Innovate will be presenting at MEDICA 2022 in Dusseldorf 🇩🇪 14 - 17 November.

This year, we will be showcasing the OvaCis® Rapid Test kit- the world's first intraoperative rapid test which can effectively discriminate benign from malignant ovarian cysts during laparoscopy procedure, as well as sharing a sneak preview of epiHERA™, our minimally invasive early endometrial cancer detection test.

Drop us a line at ovacis@inex.sg to book an appointment or come visit us at Hall 17/A02-6 in the Singapore Pavilion.

Check us out at: http://bitly.ws/wkUf

, , , , , ,